Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

VERV

Verve Therapeutics Inc

May 10 • 04:00PM ET

6.01

Dollar change -0.35
Percentage change -5.50	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VB ARKG ARKK VBK VXF IWM IWN VTWO IBB

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.88	Insider Own	30.24%	Shs Outstand	81.97M	Perf Week	-6.24%
Market Cap	472.09M	Forward P/E	-	EPS next Y	-2.85	Insider Trans	-0.01%	Shs Float	54.79M	Perf Month	-25.53%
Income	-196.83M	PEG	-	EPS next Q	-0.66	Inst Own	75.03%	Short Float	30.19%	Perf Quarter	-51.53%
Sales	16.05M	P/S	29.41	EPS this Y	17.60%	Inst Trans	24.83%	Short Ratio	12.47	Perf Half Y	-64.12%
Book/sh	6.96	P/B	0.86	EPS next Y	-10.82%	ROA	-28.80%	Short Interest	16.54M	Perf Year	-67.35%
Cash/sh	7.72	P/C	0.78	EPS next 5Y	-	ROE	-36.03%	52W Range	5.84 - 21.42	Perf YTD	-56.89%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-67.06%	ROI	-30.44%	52W High	-71.94%	Beta	1.95
Dividend TTM	-	Quick Ratio	19.82	Sales past 5Y	126.44%	Gross Margin	41.59%	52W Low	2.91%	ATR (14)	0.59
Dividend Ex-Date	-	Current Ratio	19.82	EPS Y/Y TTM	8.45%	Oper. Margin	-1381.45%	RSI (14)	29.68	Volatility	7.62% 7.22%
Employees	255	Debt/Eq	0.13	Sales Y/Y TTM	379.79%	Profit Margin	-1226.43%	Recom	1.36	Target Price	26.89
Option/Short	Yes / Yes	LT Debt/Eq	0.11	EPS Q/Q	30.31%	Payout	-	Rel Volume	1.21	Prev Close	6.36
Sales Surprise	170.39%	EPS Surprise	15.89%	Sales Q/Q	305.63%	Earnings	May 08 BMO	Avg Volume	1.33M	Price	6.01
SMA20	-8.02%	SMA50	-40.92%	SMA200	-51.86%	Trades		Volume	1,603,987	Change	-5.50%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-08-24	Initiated	H.C. Wainwright	Buy	$15
Apr-13-23	Initiated	Canaccord Genuity	Buy	$29
Feb-01-23	Initiated	Cantor Fitzgerald	Neutral	$21
Dec-15-22	Initiated	Goldman	Sell	$13
Oct-06-22	Initiated	Credit Suisse	Neutral	$48
Aug-25-22	Upgrade	Stifel	Hold → Buy	$32 → $56
Jun-17-22	Initiated	BMO Capital Markets	Outperform	$48
Feb-18-22	Initiated	RBC Capital Mkts	Outperform	$42
Sep-24-21	Initiated	Stifel	Hold	$58
Jul-12-21	Initiated	William Blair	Outperform	$92
Jul-12-21	Initiated	JP Morgan	Neutral	$50
Jul-12-21	Initiated	Jefferies	Buy	$72
Jul-12-21	Initiated	Guggenheim	Buy	$84

Show Previous Ratings

May-08-24 01:54PM	VERV Stock Earnings: Verve Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:10AM	Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:10AM	Verve Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-07-24 07:20AM	Verve moves forward with backup base editing therapy (BioPharma Dive)
07:00AM	Loading…
07:00AM	Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102 (GlobeNewswire)
May-03-24 04:01PM	Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-19-24 10:30AM	Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Verve Therapeutics, Inc. for potential violations of federal securities laws (PR Newswire)
Apr-06-24 09:50AM	After a Serious Setback, Is Verve Therapeutics a Buy? (Motley Fool)
Apr-03-24 01:40PM	Verve (VERV) Pauses Enrollment in Cholesterol Study, Stock Falls (Zacks)
Apr-02-24 04:04PM	Verve Plunges To Record Low After Cholesterol-Lowering Gene Editor Causes Side Effects (Investor's Business Daily) -34.95%
10:36AM	Verve Plunges To Record High After Cholesterol-Lowering Gene Editor Causes Side Effects (Investor's Business Daily)
09:31AM	Verve Falls as Gene-Editing Trial Paused on Safety Issues (Bloomberg)
09:01AM	Verve Plummets To Record Low After Its Gene-Editing Drug Causes Side Effects (Investor's Business Daily)
07:35AM	UPDATE 1-Verve Therapeutics pauses enrollment in early-stage gene therapy study for high cholesterol levels (Reuters)
07:00AM	Loading…
07:00AM	Verve Therapeutics pauses enrollment in early-stage gene therapy study for high cholesterol levels (Reuters)
07:00AM	Verve Therapeutics Announces Updates on its PCSK9 Program (GlobeNewswire)
03:03AM	Verve pauses base editing trial, shifts strategy after treatment side effect (BioPharma Dive)
Mar-28-24 04:51PM	Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-21-24 04:19PM	3 Stocks That Could Be the Next Big Thing in Gene Editing (InvestorPlace)
Mar-01-24 04:01PM	Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-27-24 07:02PM	Verve Therapeutics Inc (VERV) Reports Progress and Financials for Q4 and Full Year 2023 (GuruFocus.com) +21.47%
08:03AM	Verve Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
07:30AM	Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-19-24 04:08PM	3 Biotech Stocks to Buy That Have CRISPR-Like Breakthrough Potential (InvestorPlace)
Feb-13-24 06:05AM	3 Gene Editing Stocks With Unprecedented Surge Potential (InvestorPlace) -9.23%
Feb-12-24 08:30AM	2 Risky Gene-Editing Stocks to Buy in the New Bull Market if You Dare (Motley Fool) +8.31%
Feb-01-24 06:30AM	Verve Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-31-24 12:28PM	3 Once-in-a-Lifetime Gene Editing Stocks with Unprecedented Surge Potential (InvestorPlace)
Jan-17-24 12:04PM	7 Mighty Healthcare Stocks Changing the Game of Medicine (InvestorPlace)
04:38PM	Loading…
Jan-11-24 04:38PM	3 Stocks to Buy in the Booming Field of Gene Editing (InvestorPlace) -5.66%
Jan-04-24 08:00AM	Analysts Agree These 8 Cathie Wood Stock Picks Will Soar In 2024 (Investor's Business Daily)
Jan-02-24 06:30AM	Verve Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-29-23 12:00PM	Verve Therapeutics (VERV) Moves to Buy: Rationale Behind the Upgrade (Zacks) -6.76%
09:55AM	Wall Street Analysts Think Verve Therapeutics (VERV) Could Surge 217.73%: Read This Before Placing a Bet (Zacks)
Dec-13-23 09:55AM	Wall Street Analysts Believe Verve Therapeutics (VERV) Could Rally 260.31%: Here's is How to Trade (Zacks) +9.82%
Dec-06-23 12:31PM	Hedge Fund and Insider Trading News: Palliser Capital, Balyasny Asset Management , Millennium Management, Blackwells Capital, Pantera Capital, NCR Voyix Corp (VYX), Verve Therapeutics, Inc. (VERV), and More (Insider Monkey) +7.95%
Dec-01-23 04:00PM	Verve Therapeutics Announces Closing of Public Offering of Common Stock, Full Exercise by Underwriters of Option to Purchase Additional Shares and Closing of Concurrent Private Placement (GlobeNewswire)
Nov-28-23 10:37PM	Verve Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Private Placement (GlobeNewswire)
04:01PM	Verve Therapeutics Announces Proposed Public Offering of Common Stock and Concurrent Private Placement (GlobeNewswire)
Nov-27-23 09:55AM	Does Verve Therapeutics (VERV) Have the Potential to Rally 260.31% as Wall Street Analysts Expect? (Zacks)
Nov-20-23 04:26PM	Verve Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses (GlobeNewswire) +5.37%
Nov-17-23 03:41PM	Why Verve Therapeutics Stock Crashed as Much as 30% This Week (Motley Fool) +6.83%
Nov-16-23 05:41AM	Verve Therapeutics: Why Great Results Aren't Enough (Motley Fool)
05:20AM	After Its Stock Crashed 42% in 1 Day, Is Verve Therapeutics a Buy? (Motley Fool)
Nov-13-23 07:20PM	Heart Disease Breakthrough by Gene-Editor Verve Knocks Its Stock for a Loop (Barrons.com) -40.83%
04:03PM	Verve Loses A Third Of Its Value As Safety Concerns Plague Its Gene-Editing Drug (Investor's Business Daily)
02:28PM	Rebel's Edge - November 13: $BA, $VERV, $MNDY, and Harbaugh Stealing Signs (TheStreet.com)
12:17PM	Verve Therapeutics, Immersion fall; Tower Semiconductor, Boeing rise, Monday, 11/13/2023 (Associated Press Finance)
12:07PM	These 2 Stocks Are Making Big Monday Moves (Motley Fool)
08:56AM	Why Is Verve Therapeutics (VERV) Stock Down 39% Today? (InvestorPlace)
Nov-12-23 03:30PM	Verve Therapeutics Announces Interim Data for VERVE-101 Demonstrating First Human Proof-of-Concept for In Vivo Base Editing with Dose-Dependent Reductions in LDL-C and Blood PCSK9 Protein in Patients with Heterozygous Familial Hypercholesterolemia (GlobeNewswire)
10:34AM	First look at Verve study data offer base editing proof of principle (BioPharma Dive)
Nov-09-23 09:55AM	Wall Street Analysts Predict a 160.72% Upside in Verve Therapeutics (VERV): Here's What You Should Know (Zacks)
08:00AM	1 Cathie Wood Stock to Buy Hand Over Fist Right Now (Motley Fool)
05:57AM	2 Growth Stocks That Already Jumped 50% in November and Could Keep Climbing Higher (Motley Fool)
Nov-07-23 07:56AM	Verve Therapeutics Inc (VERV) Reports Q3 2023 Financial Results (GuruFocus.com) +24.83%
06:36AM	Verve Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
06:30AM	Verve Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-06-23 08:02AM	Cathie Wood's ARK Innovation Just Had Its Best Week Ever Thanks To Roku, These Huge Winners (Investor's Business Daily)
Nov-01-23 07:06AM	Verve Therapeutics (VERV) Surges 28.0%: Is This an Indication of Further Gains? (Zacks)
05:40AM	Inside Cathie Woods Portfolio: 3 Stocks She Is Betting Millions On (InvestorPlace)
Oct-31-23 07:09PM	Why Beam and Verve Therapeutics Shares Soared While Eli Lilly Soured Today (Motley Fool) +27.95%
04:04PM	Verve Stock Soars On $250 Million Eli Lilly Deal (Investor's Business Daily)
06:01AM	Verve and Lilly Relationship Expands to Include Verve's In Vivo Gene Editing Programs Targeting PCSK9 and ANGPTL3 (GlobeNewswire)
05:00AM	Lilly buys out Beam in heart drug alliance with Verve (BioPharma Dive)
Oct-30-23 03:46PM	Top 20 Genomics Companies in the World (Insider Monkey) +6.45%
08:30AM	With 1 Roadblock Down, Is Verve Therapeutics a Buy Now? (Motley Fool)
Oct-25-23 01:45AM	These Gene-Editing Stocks Are Survivors. Take Another Look. (Barrons.com)
Oct-23-23 07:38AM	Verve Surges After FDA Lifts Hold on Gene-Editing Therapy (Bloomberg)
06:30AM	Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia (GlobeNewswire)
Oct-10-23 09:45AM	2 Incredible Growth Stocks Near 52-Week Lows to Buy Now (Motley Fool)
Sep-27-23 07:49AM	Verve Therapeutics (VERV) Soars 13.8%: Is Further Upside Left in the Stock? (Zacks)
Sep-26-23 06:30AM	Verve to Present Interim Data from the heart-1 Phase 1b Clinical Trial of VERVE-101 in HeFH Patients at the American Heart Associations Scientific Sessions 2023 (GlobeNewswire) +13.75%
Sep-21-23 04:05PM	Verve Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference (GlobeNewswire)
Sep-18-23 06:30AM	Verve Expands Leadership Team with Appointment of Frederick T. Fiedorek, M.D., as Chief Medical Officer (GlobeNewswire)
Aug-31-23 10:30AM	1 Cathie Wood Stock That Could Go Parabolic Soon (Motley Fool)
Aug-11-23 09:10AM	Investors in Verve Therapeutics (NASDAQ:VERV) have unfortunately lost 47% over the last year (Simply Wall St.)
Aug-10-23 07:50AM	Verve Therapeutics (VERV) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
06:40AM	Verve Therapeutics: Q2 Earnings Snapshot (AP Finance)
06:30AM	Verve Therapeutics Highlights Recent Company Progress and Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-03-23 06:30AM	Verve Therapeutics to Present at the Canaccord 43rd Annual Growth Conference (GlobeNewswire)
Jul-25-23 09:55AM	How Much Upside is Left in Verve Therapeutics (VERV)? Wall Street Analysts Think 93.5% (Zacks)
Jul-13-23 09:53AM	Cathie Wood Is Buying This Biotech, but Here's Why I'm Not (Motley Fool)
Jun-16-23 06:02AM	Verve inks gene-editing deal with Lilly worth up to $525M (American City Business Journals)
Jun-15-23 04:07PM	Eli Lilly Just Lent Its Big Pharma Cachet To Verve's Nascent Gene-Editing Program For $60 Million (Investor's Business Daily) +16.02%
06:30AM	Verve Establishes Global Collaboration with Lilly to Advance Verves In Vivo Gene Editing Program Targeting Lp(a) for the Treatment of Atherosclerotic Cardiovascular Disease (GlobeNewswire)
Jun-09-23 08:02AM	12 Best Short Squeeze Stocks to Buy Now (Insider Monkey)
Jun-01-23 06:30AM	Verve Therapeutics to Participate in the 2023 Jefferies Healthcare Conference (GlobeNewswire)
May-23-23 06:30AM	Verve Therapeutics to Participate in the Stifel 2023 Tailoring Genes: Virtual Genetic Medicines Day (GlobeNewswire)
May-15-23 07:45AM	Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
06:36AM	Verve Therapeutics: Q1 Earnings Snapshot (AP Finance)
06:30AM	Verve Therapeutics Announces Pipeline Progress and Expansion and Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-11-23 07:21AM	We're Not Very Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Rate (Simply Wall St.)
May-09-23 06:30AM	Verve Therapeutics to Participate in the RBC Capital Markets 2023 Global Healthcare Conference (GlobeNewswire) +9.50%
Apr-20-23 06:24PM	Top 10 CRISPR Stocks To Buy (Insider Monkey)
Mar-31-23 12:04PM	Verve Therapeutics, Inc. (NASDAQ:VERV) insider upped their holding by 2.4% earlier this year (Simply Wall St.)
Mar-27-23 06:30AM	Verve Therapeutics to Participate in the Guggenheim 2023 Genomic Medicines and Rare Disease Day (GlobeNewswire)
Mar-04-23 07:32AM	Verve Therapeutics (NASDAQ:VERV) shareholders are up 4.6% this past week, but still in the red over the last year (Simply Wall St.)
Mar-03-23 06:30AM	Verve Therapeutics Reports New Preclinical Data Demonstrating Potent and Durable Editing of ANGPTL3 Gene with VERVE-201 in Wild-type and LDLR-deficient Non-Human Primates (GlobeNewswire)

Verve Therapeutics, Inc. is a genetic medicines company, which engages in the development of approach to the care of cardiovascular diseases. The company was founded by Burt A. Adelman, Keith J. Joung, Sekar Kathiresan, Kiran Musunuru, Anthony Philippakis, Issi Rozen, and Barry Ticho in 2018 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Nickerson Joan	Chief Administrative Officer	Apr 02 '24	Sale	8.24	1,514	12,475	8,659	Apr 03 05:00 PM
Dorval Allison	Chief Financial Officer	Nov 29 '23	Sale	11.45	554	6,343	4,060	Dec 01 04:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VERV

Verve Therapeutics Inc

Upgrade your FINVIZ experience